Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of Icaritin in preparation of drugs for curing GP130 related diseases

A technology of GP-130 and Acradine, which is applied in the field of medicine to achieve good pharmaceutical effects

Inactive Publication Date: 2016-11-23
BEIJING SHENOGEN PHARMA GRP
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] In the prior art, there is no further research on other targets other than ER-α36 by Alcoradine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Icaritin in preparation of drugs for curing GP130 related diseases
  • Application of Icaritin in preparation of drugs for curing GP130 related diseases
  • Application of Icaritin in preparation of drugs for curing GP130 related diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Preparation of Alcoradine

[0033] Acradine, also known as icariin, is extracted and separated from the traditional Chinese medicine Epimedium.

[0034] The preparation method of Epimedium is disclosed in the patent whose publication number is CN 101302548. In the method, icariin is used as a raw material, hydrolyzed by β-glucosidase, the precipitate obtained by centrifuging the hydrolyzed product is dissolved in acetone, and the supernatant is obtained by centrifuging and filtering. Then the supernatant liquid obtained by centrifugation is recrystallized with water to obtain the pure Epimedium. The icariin in the present invention was purchased from Shaanxi Jiahe Plant Chemical Co., Ltd., with a purity of 90%.

Embodiment 2

[0036] Detect the inhibitory effects of alcoladine on hepatocarcinoma PLC / PRF / 5 cells.

[0037] Experimental steps: cell culture: first, the PLC / PRF / 5 liver cancer cells are cultured to a cell density of 80% in an amino acid and glucose medium (i.e., DMEM medium) containing a volume concentration of 10% fetal bovine serum; The cells were divided into phenol red-free medium containing activated carbon-treated fetal bovine serum at a volume concentration of 2.5%, and cultured for 24 hours.

[0038] Add dimethyl sulfoxide (DMSO) and alcradine: add DMSO control (that is, the DMSO solution not containing alcradine) and 5 μmol / L alcradine DMSO solution respectively in the culture system, and make each The final volume concentration of DMSO in the reaction system was 0.1%.

[0039] The cells were harvested at 12, 24 and 48 hours, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and GP130 antibodies were added to the cells for detection by western blot.

[0040] Test result pass...

Embodiment 3

[0042] To detect the inhibitory effect of alcoladine on the liver cancer cell HUH7.

[0043] Experimental steps: cell culture: firstly culture HUH7 cells in amino acid and glucose medium (ie DMEM medium) containing 10% volume concentration of fetal bovine serum to a cell density of 80%; In the phenol red-free medium with a volume concentration of 2.5% fetal bovine serum, culture for 24 hours.

[0044] Add dimethyl sulfoxide (DMSO) and alcradine: add DMSO control (that is, the DMSO solution that does not contain alcradine) and the alcladine DMSO solution of 5 μ M concentration respectively in the culture system, and make each The final volume concentration of DMSO in the reaction system was 0.1%.

[0045] The cells were harvested at 12, 24 and 48 hours, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and GP130 antibodies were added to the cells for detection by western blot.

[0046] Test result passed figure 2 It can be seen in the upper half of the figure that the ex...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of Icaritin in preparation of drugs for curing GP130 related diseases, particularly GP130 related liver cancer, and the Icaritin shows excellent pharmaceutical effect. According to the application of the Icaritin in preparation of the drugs for curing the GP130 related diseases, research direction is further provided for Icaritin in targeting of cancer curing.

Description

technical field [0001] The invention relates to the use of alcradine in the preparation of medicines for treating GP130-related diseases, and belongs to the field of medicine. Background technique [0002] Glycoprotein GP130 is a transmembrane protein and a receptor for a class of cytokines. It forms the subunit of a class of cytokine receptors of the IL-6 receptor family. And GP130 is very important for the signaling of cytokine binding pathway. [0003] Studies have confirmed that the abnormal activation of the interleukin-6 / GP130 (IL-6 / GP130) signaling pathway plays a key role in the development of various tumors. An article titled "IL6-GP130-STAT3 pathway in liver cells forms T-cell regulated liver injury triggers liver protection" was published in "The Journal of Clinical Investigation", (The IL- 6-GP130-STAT3 Pathway in Hepatocytes Triggers Liver Protection in T Cell-mediated Liver Injury) mentioned the protective effect of IL-6-GP-130-dependent signaling pathway in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/352A61P35/00A61P1/16
Inventor 孟坤郭玉明朱海李抒
Owner BEIJING SHENOGEN PHARMA GRP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com